헌팅턴병 치료 시장 : 점유율 분석, 업계 동향과 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the huntington's disease treatment market size was valued at USD 820 million in 2025 and estimated to grow from USD 890 million in 2026 to reach USD 1.31 billion by 2031, at a CAGR of 8.12% during the forecast period (2026-2031).

This report is Segmented by Type (Symptomatic Treatment and Disease-Modifying Therapies), Route of Administration (Oral, Intravenous, and More), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and More), Stage of Disease (Early-Stage, Mid-Stage, and More), and Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Huntington's Disease Treatment Market Trends and Insights

HTT-lowering clinical pipeline breakthroughs

Multiple platforms now show meaningful mutant huntingtin reductions. WVE-003 produced a 46% cerebrospinal-fluid decrease while sparing wild-type protein, addressing earlier safety concerns. Oral PTC 518 delivered up to 43% blood reductions and slowed Total Motor Score progression by more than 70% at 12 months. Investor confidence surged when Novartis paid USD 2.9 billion for PTC 518, crystallising the therapy's perceived commercial potential. The US FDA's readiness to accept huntingtin lowering as a surrogate endpoint compresses timelines and mitigates single-platform risk, accelerating the Huntington's disease treatment market trajectory.

Once-daily VMAT2 launches in Asia

Teva's alliance with Jiangsu Nhwa earned the first deuterated-drug approval in China for AUSTEDO, broadening access to chorea management and creating a springboard for future disease-modifying entries. INGREZZA generated USD 2.3 billion in 2024, with sprinkle formulations easing administration for dysphagic patients. Prevalence disparity-0.40 per 100,000 in Asia versus 5.70 per 100,000 in Europe-necessitates physician-education heavy models rather than mass-market campaigns. Strategic Asian launches therefore extend the Huntington's disease treatment market footprint beyond Western strongholds.

Ultra-high cost of gene and cell therapies

List prices eclipsing USD 1 million per patient threaten equitable access. Less than 5% of 10,000 rare diseases have FDA-cleared therapies, underscoring reimbursement hurdles. Payors explore value-based models and reinsurance, yet fragmented adoption keeps many markets out of reach and slows early uptake within the Huntington's disease treatment market.

Other drivers and restraints analyzed in the detailed report include:

1. Fast-track and orphan designations in US / EU
2. Rising incidence in ageing cohorts
3. Limited specialist centres outside US/EU

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Symptomatic drugs retained 61.92% of the Huntington's disease treatment market share in 2025, yet disease-modifying agents are scaling faster at a 15.84% CAGR through 2031. This pivot enlarges the Huntington's disease treatment market as oral small molecules, antisense oligonucleotides, RNA interference constructs, and AAV gene therapies converge. INGREZZA's USD 2.3 billion 2024 revenue underscores robust demand for chorea control, while AMT-130's 80% slowing of disease progression versus external controls illustrates gene therapy's disruptive promise. Beta-blocker repurposing introduced 34% motor-symptom risk reduction in pre-manifest carriers, bridging symptomatic and modifying paradigms. As combination regimens coalesce, developers will need to optimise sequencing, safety monitoring, and payor evidence packages.

Integrated care models may soon pair once-daily VMAT2 inhibitors with periodic huntingtin-lowering infusions to synchronise acute symptom relief and long-range neuroprotection. The Huntington's disease treatment market size for disease-modifying products is projected to reach USD 590 million by 2031, accounting for nearly 45.00% of incremental revenue growth. Uptake hinges on selective lowering approaches that spare wild-type huntingtin and offer outpatient dosing. Regulatory flexibility around biomarker-driven approvals further lowers market-entry barriers for next-wave candidates targeting DNA-repair pathways and somatic CAG expansion.

Oral formulations secured 54.05% of the Huntington's disease treatment market size in 2025, aligned with strong adherence and primary-care prescription patterns. Intravenous segment growth at 11.73% CAGR is catalysed by one-time gene therapies and recurrent antisense infusions demanding precise central-nervous-system distribution. Intrathecal delivery remains niche yet essential for allele-selective oligonucleotides that require cerebrospinal-fluid access without systemic exposure.

Drug-delivery engineering now focuses on patient-friendly packaging such as pre-filled syringes and lyophilised powder kits. Hospitals invest in infusion suites with real-time neuro-monitoring, while specialty pharmacies manage cold chain and long-term follow-up. As post-marketing data confirm durability and safety, intravenous share is forecast to approach 29.40% of the Huntington's disease treatment market by 2031. Subcutaneous-to-intravenous switching studies will further refine cost-effectiveness boundaries.

Complete Report Scope:

• By Treatment Type
  • Symptomatic Treatments
    • VMAT2 Inhibitors
    • Antidopaminergics (Antipsychotics)
    • Antidepressants & Anxiolytics
    • Anticonvulsants / Others
  • Disease-Modifying Therapies
    • Gene Silencing / ASO
    • Gene Therapy (AAV, LNP etc.)
    • Stem-Cell Therapy
    • Small-Molecule HTT Modifiers
• By Route of Administration
  • Oral
  • Intravenous
  • Intrathecal
  • Subcutaneous
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Specialty & Online Pharmacies
• By Stage of Disease
  • Pre-symptomatic / Prodromal
  • Early-Stage
  • Mid-Stage
  • Late-Stage
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America generated 38.20% of global revenue in 2025, underpinned by FDA leadership on expedited pathways, concentrated specialist clinics, and strong payer adoption of VMAT2 inhibitors. Nevertheless, diagnosis delays in Black populations highlight systemic inequities that temper absolute growth potential. Canada and Mexico collaborate with US centres to widen access to gene therapy trials, fostering cross-border referral channels that steadily enlarge the Huntington's disease treatment market.

Europe leverages regulatory harmonisation to fast-track disease-modifying dossiers, with the EMA reviewing pridopidine for potential H2 2025 launch. Multi-country consortia developed the Huntington Support App, exemplifying cost-efficient digital outreach that offsets uneven clinic density. Germany, United Kingdom, and France lead on trial sponsorship, while Eastern Europe's modernising neurologic infrastructure promises double-digit gains. Diverse reimbursement systems foster pilot outcomes-based contracts that could migrate to other regions once validated.

Asia-Pacific is the fastest-growing cluster at 14.55% CAGR through 2031, spearheaded by China's first deuterated-drug approval and Japan's sophisticated rare-disease registries Teva. South Korea's dedicated society advances local clinician training, and Australia's regulatory parallel-processing accelerates international studies. Lower prevalence forces high-touch engagement: physician-led patient mapping, centre-of-excellence accreditation, and remote monitoring fill gaps where infrastructure lags. These initiatives collectively elevate the Huntington's disease treatment market presence across emerging economies. Latin America, the Middle East, and Africa remain nascent yet display improving diagnostic rates and advocacy-driven policy discussions that foreshadow gradual uptake once cost barriers recede.

1. Pfizer
2. Teva Pharmaceutical Industries
3. Neurocrine Biosciences
4. Alnylam Pharmaceuticals
5. Ionis Pharmaceuticals
6. Roche / Genentech
7. Novartis
8. uniQure
9. Sangamo Therapeutics
10. PTC Therapeutics
11. Prilenia Therapeutics
12. Wave Life Sciences
13. Sage Therapeutics
14. Biogen
15. Lundbeck
16. Azevan Pharmaceuticals
17. Voyager Therapeutics
18. IntraBio
19. Kyowa Kirin
20. Vaxxinity

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Incidence In Ageing-Cohort Populations
  • 4.2.2 Accelerating HTT-Lowering Clinical Pipeline Breakthroughs
  • 4.2.3 Commercial Launch Of Once-Daily VMAT2 Inhibitors In Asia
  • 4.2.4 Fast-Track & Orphan Designations In US / EU
  • 4.2.5 AI-Enabled Biomarker Discovery Improving Trial Success
  • 4.2.6 ?eta-Blocker Repurposing Showing Disease-Modifying Signal
• 4.3 Market Restraints
  • 4.3.1 Ultra-High Cost Of Gene & Cell Therapies
  • 4.3.2 Limited Specialist Centres Outside North America & EU
  • 4.3.3 Sub-Optimal Adherence To Symptomatic Poly-Pharmacy
  • 4.3.4 Data-Safety Concerns For CRISPR In Neuronal Tissue
• 4.4 Porter's Five Forces
  • 4.4.1 Threat of New Entrants
  • 4.4.2 Bargaining Power of Buyers
  • 4.4.3 Bargaining Power of Suppliers
  • 4.4.4 Threat of Substitutes
  • 4.4.5 Intensity of Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Treatment Type
  • 5.1.1 Symptomatic Treatments
    • 5.1.1.1 VMAT2 Inhibitors
    • 5.1.1.2 Antidopaminergics (Antipsychotics)
    • 5.1.1.3 Antidepressants & Anxiolytics
    • 5.1.1.4 Anticonvulsants / Others
  • 5.1.2 Disease-Modifying Therapies
    • 5.1.2.1 Gene Silencing / ASO
    • 5.1.2.2 Gene Therapy (AAV, LNP etc.)
    • 5.1.2.3 Stem-Cell Therapy
    • 5.1.2.4 Small-Molecule HTT Modifiers
• 5.2 By Route of Administration
  • 5.2.1 Oral
  • 5.2.2 Intravenous
  • 5.2.3 Intrathecal
  • 5.2.4 Subcutaneous
• 5.3 By Distribution Channel
  • 5.3.1 Hospital Pharmacies
  • 5.3.2 Retail Pharmacies
  • 5.3.3 Specialty & Online Pharmacies
• 5.4 By Stage of Disease
  • 5.4.1 Pre-symptomatic / Prodromal
  • 5.4.2 Early-Stage
  • 5.4.3 Mid-Stage
  • 5.4.4 Late-Stage
• 5.5 Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 South Korea
    • 5.5.3.5 Australia
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.3.1 Pfizer Inc
  • 6.3.2 Teva Pharmaceutical Industries
  • 6.3.3 Neurocrine Biosciences
  • 6.3.4 Alnylam Pharmaceuticals
  • 6.3.5 Ionis Pharmaceuticals
  • 6.3.6 Roche / Genentech
  • 6.3.7 Novartis AG
  • 6.3.8 uniQure
  • 6.3.9 Sangamo Therapeutics
  • 6.3.10 PTC Therapeutics
  • 6.3.11 Prilenia Therapeutics
  • 6.3.12 Wave Life Sciences
  • 6.3.13 Sage Therapeutics
  • 6.3.14 Biogen Inc.
  • 6.3.15 Lundbeck
  • 6.3.16 Azevan Pharmaceuticals
  • 6.3.17 Voyager Therapeutics
  • 6.3.18 IntraBio
  • 6.3.19 Kyowa Kirin
  • 6.3.20 Vaxxinity

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-need Assessment